Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia Relapse Clinical Trial

— Vandevol  

Official title:

A Phase I Dose Escalation Study of Clofarabine Given in Combination With Multi-agent Therapy for Remission Induction in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse or Refractory to First Line Therapy -

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01279096
• Other study ID #: 2009-010826-20
• Secondary ID: 2008_40/0905
• Status: Completed
• Phase: Phase 1
• First received: January 17, 2011
• Last updated: December 8, 2014
• Start date: January 2010
• Est. completion date: June 2013

Study information

• Verified date: December 2014
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone and to assess the feasibility and safety of this combination regimen to treat children with high risk relapsed or refractory acute lymphoblastic leukemia (ALL).

Description:

I.3 Primary Objectives :

To determine the MTD of escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5, as a replacement of cytarabine as part of a combination of etoposide, asparaginase, mitoxantrone and dexamethasone (VANDA regimen).

I.4 Secondary Objectives :

1. To determine the safety and tolerability of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone (VANDA regimen) and determine the duration, seriousness, and relationship of adverse events that occur during the treatment and follow-up periods ; we search DLT

2. To determine the Overall Response rate (OR) (Complete Remission + Complete Remission without platelet's normalization) of clofarabine plus etoposide ,asparaginase, mitoxantrone and dexamethasone (VANDA regimen) in pediatric patients with refractory or relapsed ALL at the established clofarabine RP2D.

3. To document the rate of Partial Response[s] in the study population

4. To document time-to-event parameters, including duration of remission, Event Free Survival (EFS), 4-month EFS, and overall survival (OS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2013
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 23 Years

Eligibility

Inclusion Criteria:

• 1 to 21 years old at the date of acute lymphoblastic leukemia initial diagnosis

• Very early medullary first relapse occurring during the first 18th months after complete remission OR patients with second relapse OR a relapse occurring 6 months or more after myeloablative stem cell transplantation will be eligible.

• Have a Karnofsky Performance Status (KPS) of =70 for patients >10 years of age or a Lansky Performance Status (LPS) of =60 for patients =10 years of age.

• No concomitant malignant disease.

• No active uncontrolled infection.

• Have adequate renal and hepatic functions

• absence of concomitant severe cardiovascular disease, i.e. congestive heart failure

• Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.

• Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

Exclusion Criteria:

• Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.

• Use of any investigational agent within 30 days.

• Known hypersensitivity to clofarabine or excipients.

• Known hypersensitivity to mitoxantrone, etoposide or excipients.

• Allergy to both E Coli-Asparaginase and Erwinia Asparaginase

• Prior transplant less than 6 months ago.

• Trisomy 21

• Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.

• Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).

• Pregnant or lactating patients.

• Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Lymphoid Leukemia Relapse
• Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Clofarabine
escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone

Locations

Country	Name	City	State
France	Besançon University Hospital	Besançon
France	Lille University Hospital	Lille

Sponsors (11)

Lead Sponsor	Collaborator
University Hospital, Lille	Assistance Publique - Hôpitaux de Paris, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, Nantes University Hospital, Rennes University Hospital, Saint-Louis Hospital, Paris, France, University Hospital, Bordeaux, University Hospital, Marseille, University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone		within the 40 days after the chemotherapy	Yes
Secondary	efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone	Complete remission rate and minimal residual disease level	40 days after the chemotherapy	No
Secondary	Event free survival		4 months	No